Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
Healthcare
$16.10 +0.47%
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
52W Low $14.72High $29.16
Volume 0.44M
Average 0.33M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$64.13M
FY 2025 · Annual
Investing Cash Flow
$65.96M
FY 2025 · Annual
Financing Cash Flow
-$1.21M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Depreciation & Amortization | 445K | 1.12M | 1.58M | 2.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 698K | 1.48M | 2.26M | 5.13M |
| Change in Working Capital | (1.14M) | (15K) | 58.98M | (3.23M) |
| Accounts Receivables | 0 | (257K) | (861K) | 1.03M |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | (1K) | 659K | 360K | (44K) |
| Other Working Capital | (1.14M) | (417K) | 59.48M | (4.22M) |
| Other Non-Cash Items | (200K) | (3.95M) | (4.07M) | (4.62M) |
| Operating Cash Flow | (18.13M) | (30M) | 14.76M | (64.13M) |
| Capital Expenditures | (2.31M) | (3.76M) | (2.86M) | (9.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (145.81M) | (288.4M) | (193.87M) |
| Sales of Investments | 0 | 80.69M | 100.86M | 269.42M |
| Other Investing Activities | 0 | 57K | 0 | 0 |
| Investing Cash Flow | (2.31M) | (68.83M) | (190.4M) | 65.96M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 336K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (151K) | 0 | (1.72M) | (1.55M) |
| Financing Cash Flow | 119.98M | 0 | 183.28M | (1.21M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 99.55M | (98.83M) | 7.65M | 625K |
| Free Cash Flow | (20.43M) | (33.77M) | 11.9M | (73.71M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$63.7M
+ D&A$2.3M
+ Stock-Based Comp$5.1M
+ Deferred Tax$0
- Working Capital-$3.2M
- Other Non-Cash-$4.6M
= Operating Cash Flow-$64.1M
- Capex-$9.6M
= Free Cash Flow-$73.7M
Analysis
FY2025 free cash flow is -$73.7M. FCF conversion is 115.7% of net income. Operating cash flow was -$64.1M, with capex of -$9.6M. The largest bridge item is Capex at -$9.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 |
Does AKTS generate free cash flow?
Aktis Oncology, Inc. (AKTS) generated -$73.71M of free cash flow in fiscal 2025.
How much operating cash flow does AKTS produce?
Operating cash flow was -$64.13M, before capital expenditures of $9.58M.
Continue the stock analysis
Jump to another research area for this company.